Cord Blood Amer Inc. (WKN: A0EAGC / CBAI) / OTCBB
OTCPicks.com: OTCPicks.com Stocks to Watch for Friday, January 30th
PSTI, CBAI, ANPI, ISSC
http://www.quote.com/news/story.action?id=MTO030u6587&pg=5
Shareholder-Letter: http://www.cordblood-america.com/11-13-2008-shareholder-letter.pdf
**************************************************
CORD BLOOD AMERICA INCORPORATED (OTCBB:CBAI) "Up 40.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CBAI.php
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
CBAI News:
January 27 - With the Embryonic Stem Cell Trial Cleared by the FDA as a Key Indicator, Cord Blood America Announces Expansion Plans for Its Stem Cell Storage Program
More Stem Cell Agenda News Expected From the Obama Administration This Week
Cord Blood America, Inc. (OTCBB:CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said that it intends a rapid expansion of its health insurance partnership program to new geographies in 2009. This announcement from Cord Blood America comes on the heels of last week's announcement that the Food and Drug Administration and the U.S. government will allow the world's first test in people of a therapy derived from human embryonic stem cells. For more information, see the social media news room at www.intelligendo.com.
Founder and CEO Matthew Schissler, in reviewing the domestic stem cell industry, predicts that 2009 will be an excellent, milestone year for stem cell storage companies, including CBAI. "Now is the right time. We have focused our business on three primary locations for several years, developing deep relationships with health insurance providers to become their recommended source for storage of umbilical cord blood stem cells."
Mr. Schissler says Cord Blood America's stem cell storage subsidiary, CorCell, will attempt to enter into contracts with two or three more geographic health insurance providers, which would double the company's current health insurance provider base.
"With a national health insurance plan and stem cell agenda as two of the primary topics from the new administration, we see a marriage of the insurance companies possibly paying for stem cell storage on the horizon, even if it is on a limited basis for high risk families. By developing the insurance sales channel, we feel we are positioning ourselves for long term success in becoming a globally dominant stem cell storage company."
Mr. Schissler went on to say that the growth will have limited cost because all infrastructure needed has been put into place over the course of many years.
CBAI has a history of being able to finance its growth, with the most recent funding of $4 million transacting in July of 2008. "With a very low cash burn, we feel we're well financed for the next few years," Schissler commented. "We'll use this time to get cash flow positive and reduce debt while growing both organically and through accretive acquisitions."
The company also is reporting tremendous success in engaging its clients, prospective clients, shareholders and prospective investors via social media with the help and intuition of NetGenPR (www.netgenpr.com). Cord Blood America is currently on Twitter, Facebook and Intelligendo, and soon to be available on FriendFeed. Cord Blood America's address on Twitter is www.twitter.com/cbai. "The conversation has begun. Groups from all over are discussing the impact of stem cells on every day life. We're glad we can lead and moderate this information, while trying to be a stem cell company of the people."
As previously reported, from 2003 to 2007, CBAI focused on growth. In 2008, the Company changed its tactics attempting to de-lever the company while becoming purely a stem cell storage company, and in the process de-emphasizing its non-core family advertising business.
As such, Cord Blood America has reported through first nine months:
* Gross profits for the first nine months have increased to $1.8 million, a 54 percent margin, compared to a 42 percent margin in 2007.
* SGA is down nearly $900,000, a 23 percent savings.
* Loss from operations is down nearly 20 percent.
* Loss per share is down 60 percent, from 0.05 to 0.02.
"We believe 2009 to be a turning point year for CBAI. We're excited to get going," Mr. Schissler concluded.
ANGIOTECH PHARMACEUTICALS INCORPORATED (NASDAQ:ANPI) "Up 18.06% on Thursday"
ANGIOTECH PHARMACEUTICALS INCORPORATED (NASDAQ:ANPI) "Up 18.06% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/ANPI.php
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.
ANPI News:
January 29 - Angiotech's Corporate Partner Boston Scientific Announces Japanese Approval for TAXUS Liberte Drug-Eluting Stent System
Angiotech Pharmaceuticals, Inc. (Nasdaq:ANPI) (TSX: ANP), a global specialty pharmaceutical and medical device company, announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS Liberte paclitaxel-eluting coronary stent system. Boston Scientific plans to launch the product in Japan once reimbursement approval is granted. The TAXUS Liberte was approved by the FDA in October 2008 and was launched in Europe and several other international markets in 2005.
"The TAXUS Liberte stent is the latest advance in drug-eluting stent technology for Japan," said Donald Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "Its safety and efficacy have been well demonstrated in multiple clinical studies and years of clinical use."
"We are pleased to see the approval of TAXUS Liberte in Japan as it demonstrates our partner's commitment to expanding its international acceptance," said Dr. William Hunter, President and CEO of Angiotech. "Japanese patients and their families struggling with coronary artery disease should soon be able to benefit from this proven technology."
TAXUS Liberte is the only second-generation drug-eluting stent approved for use in Japan. The TAXUS Liberte stent will replace the TAXUS Express(2)(TM) stent, marketed in Japan since May 2007. Significant design improvements over the first-generation stent include thinner struts and a more uniform stent geometry.
CBAI verdient an jedem Kunden im ersten Jahr 1925$.
150$ für die Registrierung
150$ für den Kurier Transport
1500$ für die Entnahme
125$ jährlich für die Speicherung
CBAI yearly revenue derzeit: $5,811,000
Gruß, TexX
Angehängte Grafik:
sc.png
sc.png
Gruß, TexX
Ganz Amerika diskutiert derzeit über Stammzellen. Kommende Ausgabe (Februar 09) des TIME Magazin:
Angehängte Grafik:
time.jpg
time.jpg
Can't provide outstanding until auditors check.
All the Best,
Matthew L. Schissler
Chairman & CEO
-----Original Message-----
From: Ax xxx [mailto:xxx@xxx.de]
Sent: Friday, January 30, 2009 12:28 AM
To: pknopick@eandecommunications.com
Subject: CORD BLOOD AMERICA (CBAI) - currently AS / OS ??
Dear Mr. Knopick
can you communicate momentary number AS and OS of CBAI to me?
Regards
Ax xxx
**************************************************
http://investorshub.advfn.com/boards/board.aspx?board_id=3650
Share Structure:
AS: 950M
OS: 309,474,243 Nov 10m 2008
Corporate Address:
9000 W. Sunset Boulevard
Suite 400
West Hollywood, CA 90069 USA
Company Contact:
P:(310) 432-4090
F:(310) 432-4098
investors@cordblood-america.com
Investor relations:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com
Transfer Agent
Interwest Transfer Company, Inc.
1981 East 4800 South
Suite 100
Salt Lake City, UT 84117
Phone: (801) - 272-9294
Fax: (801) - 277-3147
Company Officers:
Matthew Schissler - Chairman & CEO - mls@cordpartners.com
Joseph R. Vicente - Director - jvicente@cordpartners.com
Sandra D. Smith - CFO
http://www.msbcbs.com/corcell/members.html
http://www.corcell.com/healthcare_partners/healthcare_partners.html
"National Labor Office of the Blue Cross Blue Shield Association
... The National Labor Office of the Blue Cross Blue Shield Association maintains a strategic alliance with CorCell to market cord blood services to organized labor and the Blue Cross and Blue Shield health insurance Plans servicing labor throughout the United States. CorCell is dedicated to bringing education and cord blood preservation services to families affiliated with unions across the country..."
Gruß, TexX
**************************************************
aktuell letzter Quartalsbericht (Quartal bis 30.09.2008):
http://www.sec.gov/Archives/edgar/data/1289496/...8001912/cbai10q.htm
Cord Blood America Announces Expansion Plans For Its Stem Cell Storage Program
Main Category: Stem Cell Research
Article Date: 30 Jan 2009 - 4:00 PST
Cord Blood America, Inc. (OTCBB: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it intends a rapid expansion of its health insurance partnership program to new geographies in 2009. This announcement from Cord Blood America comes on the heels of last week's announcement that the Food and Drug Administration and the U.S. government will allow the world's first test in people of a therapy derived from human embryonic stem cells. For more information, see the social media news room at http://www.intelligendo.com.
Founder and CEO Matthew Schissler, in reviewing the domestic stem cell industry, predicts that 2009 will be an excellent, milestone year for stem cell storage companies, including CBAI. "Now is the right time. We have focused our business on three primary locations for several years, developing deep relationships with health insurance providers to become their recommended source for storage of umbilical cord blood stem cells."
Mr. Schissler says Cord Blood America's stem cell storage subsidiary, CorCell, will attempt to enter into contracts with two or three more geographic health insurance providers, which would double the company's current health insurance provider base.
"With a national health insurance plan and stem cell agenda as two of the primary topics from the new administration, we see a marriage of the insurance companies possibly paying for stem cell storage on the horizon, even if it is on a limited basis for high risk families. By developing the insurance sales channel, we feel we are positioning ourselves for long term success in becoming a globally dominant stem cell storage company."
Mr. Schissler went on to say that the growth will have limited cost because all infrastructure needed has been put into place over the course of many years.
CBAI has a history of being able to finance its growth, with the most recent funding of $4 million transacting in July of 2008. "With a very low cash burn, we feel we're well financed for the next few years," Schissler commented. "We'll use this time to get cash flow positive and reduce debt while growing both organically and through accretive acquisitions."
The company also is reporting tremendous success in engaging its clients, prospective clients, shareholders and prospective investors via social media with the help and intuition of NetGenPR (http://www.netgenpr.com). Cord Blood America is currently on Twitter, Facebook and Intelligendo, and soon to be available on FriendFeed. Cord Blood America's address on Twitter is http://www.twitter.com/cbai. "The conversation has begun. Groups from all over are discussing the impact of stem cells on every day life. We're glad we can lead and moderate this information, while trying to be a stem cell company of the people."
As previously reported, from 2003 to 2007, CBAI focused on growth. In 2008, the Company changed its tactics attempting to de-lever the company while becoming purely a stem cell storage company, and in the process de-emphasizing its non-core family advertising business.
As such, Cord Blood America has reported through first nine months:
-- Gross profits for the first nine months have increased to $1.8 million, a 54 percent margin, compared to a 42 percent margin in 2007.
-- SGA is down nearly $900,000, a 23 percent savings.
-- Loss from operations is down nearly 20 percent.
-- Loss per share is down 60 percent, from 0.05 to 0.02.
"We believe 2009 to be a turning point year for CBAI. We're excited to get going," Mr. Schissler concluded.
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/. To see our social media news room go to http://www.intelligendo.com
http://www.intelligendo.com
Cord Blood America Inc.
CBAI: OTC Bulletin Board Market; Healthcare/Healthcare Facilities
New York Times
Sunday, February 1, 2009
Company Information
Cord Blood America, Inc. (CBAI) is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for use in stem cell therapy. It is a holding company whose subsidiaries include Cord Partners, Inc. (Cord), CorCell Co. Inc., CorCell Ltd., CBA Professional Services, Inc., doing business as BodyCells, Inc. (BodyCells), CBA Properties, Inc. (Properties), and Career Channel Inc, doing business as Rainmakers International (Rain). On February 28, 2007, the Company acquired CorCell, Inc. On August 1, 2007, it entered into an agreement with Progenitor Cell Therapy, LLC (PCT) for testing, processing and storage of cord blood samples. As a result of the agreement with PCT, the Company terminated its agreement with Bergen Community Regional Blood Center. On August 20, 2007, CBAI acquired specific assets from CureSource, Inc.
Cord Blood America Inc.
501 Santa Monica Blvd Suite 700 Santa Monica CA 90401
Phone: +1 (310) 432-4090
@0815ax: danke für den link
Interessant auch zu erfahren, wie man sich die Entwicklung des Kundenstammes bis 2013 vorstellt, denn daran kann man unter anderem erkennen, das der CEO keineswegs an Größenwahn leidet und den Investoren hier was aufschwätzen will. Ich denke eher, das die Schätzungen sogar noch sehr konservativ gehalten sind, denn es kann niemand absehen, was in dieser Branche losbrechen wird...
Gruß, TexX
http://www.savingthecure.com
http://www.legis.ga.gov/legis/2007_08/sum/sb148.htm
...The bill provides that, after July 1, 2009, every expectant Georgia mother will be given information by her doctor on the full range of options with regard to postnatal tissue and fluid, including private storage and public donation. Every Georgia mother will be given the opportunity to “save the cure.”...
Gruß, TexX
...aktuelle News/Berichte etc.
Thu Feb 5, 8:01 AM
SANTA MONICA, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI.OB), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, explained that the Company is very close to becoming cash flow positive.
The complete interview is available at http://www.stoxrox.com/cbai-feb-b.mp3 . "2009 is a tipping point year for Cord Blood America. We will continue our organic growth strategy, adding new health insurance partners and possible new acquisitions, while continuing to reduce debt," Mr. Schissler said.
Cord Blood America's CEO said he was encouraged that more Federal spending on stem cell research under President Obama could lead to more stem cell therapies which, in turn, will lead to more families storing stem cells. "The stem cell agenda is front and center with the new Administration," Mr. Schissler said.
Cord Blood America's CEO also referenced the cover story of the new Time magazine, which cited breakthroughs using stem cells to treat Parkinson's, heart disease and diabetes. "Investors should understand, in storing umbilical cord blood stem cells, we have a significant biological annuity with low bad debt ratio, strong gross profits, and a low cost structure in place that will allow us to take full advantage of the expected increase in the storage of stem cells," the Company's founder said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI.OB) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI.OB), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Gruß, TexX
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7204017
The Washington Times - Feb 05 8:33 PM
WILLIAMSBURG| President Obama on Thursday gave lawmakers his "guarantee" he will sign an executive order overturning President Bush's embryonic stem cell research policy.
Meeting with House Democrats holding a retreat here, Mr. Obama answered a question from Rep. James R. Langevin, a Rhode Island Democrat who is a paraplegic, by saying he will sign the order, according to three sources who were in the closed-door part of the meeting.
"I guarantee you that we will sign an executive order for stem cells," Mr. Obama said, according to the sources who requested anonymity because they were not authorized to talk about the closed-door portion of the meeting.
Mr. Obama said the executive order would be coordinated with Congress on timing, and said it was important that Congress also pass a law codifying his order so that a future president couldn't simply reverse the policy back.
...
Gruß, TexX
http://www.cnn.com/2009/POLITICS/02/07/stimulus.cuts/index.html
Gruß, TexX